Bill > S2283

This bill establishes a Psilocybin Behavioral Health Access and Therapy Pilot Program in New Jersey, allocating $6 million to fund research into the therapeutic potential of psilocybin for various behavioral health conditions, such as substance use disorders, depression, and anxiety. The program will involve three selected hospitals, one in each region of the state (northern, central, and southern), to conduct this research in compliance with federal regulations from the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA). The bill also establishes a Psychedelic Therapy and Research Advisory Board to oversee the program and make recommendations for a statewide psilocybin care system, aiming to improve mental and social well-being for New Jersey residents. The funding will be distributed equally among the participating hospitals, with $2 million each.

Budget and Finance, Health and Social Services

https://www.njleg.state.nj.us/bill-search/2024/S2283